State-matched redox nanomedicine for cell fate control and multicompartment therapeutic windows.
9 affiliations
- 1Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Nuclear Physics and Medical Research Key Laboratory of Sichuan Province, Sichuan University, Chengdu, Sichuan, China.
- 2College of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, 1166 Liutai Avenue, Wenjiang District, Chengdu, Sichuan Province, China.
- 3Department of Oncology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, 646099, China.
- 4Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- 5Nuclear Power Institute of China, Chengdu, Sichuan, China; Sichuan Haitong Isotope Technology Co., Ltd., Chengdu, Sichuan, China.
- 6Sichuan Haitong Isotope Technology Co., Ltd., Chengdu, Sichuan, China.
- 7Nuclear Power Institute of China, Chengdu, Sichuan, China.
- 8Department of Oncology, West China Fourth Hospital, Sichuan University, Chengdu, China. Electronic address: [email protected].
- 9Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Nuclear Physics and Medical Research Key Laboratory of Sichuan Province, Sichuan University, Chengdu, Sichuan, China. Electronic address: [email protected].
Abstract
Tumors persist under sustained redox stress by coupling increased reactive-species production to antioxidant buffering, metabolic plasticity and multicellular support. This creates therapeutic vulnerabilities whose tractability depends on the biological state of the exposed compartment. Here, we frame redox nanomedicine as state-matched manipulation of oxidant flux, antioxidant buffering, oxygen and substrate availability, localization, duration and spatial coverage. We propose that therapeutic outcome emerges from chemistry, exposure and the presence of an executable redox dependency together with the machinery required for adaptation, apoptosis, ferroptosis, pyroptosis or cuproptosis. Redox perturbations also propagate through immune, vascular, stromal and metabolic compartments, generating both therapeutic benefits and liabilities. We therefore integrate redox-state dependence, cell-fate assignment, multicompartment effects and translational target engagement into a unified framework. A state-matched development strategy begins with a defined biological dependency, measures local exposure and target engagement, and uses pharmacokinetic, safety and biomarker data to refine product design and patient selection. This framework positions redox nanomedicine as mechanistically testable control of tumor redox states within a defined therapeutic window.
Related
- Therapeutic Redox Reprogramming in Breast Cancer: From Antioxidant Modulation to Precision Nanomedicine.
- Neuromuscular Junction Degeneration in Skeletal Muscle Atrophy: Disease-Specific Mechanisms, Evidence-Informed Stratification, and Therapeutic Windows
- The conformational–condensate code of GRB2: State switching, spatial organization, and therapeutic windows
- Online co-care management and glycemic control in patients with type 2 diabetes mellitus: A propensity score-matched retrospective cohort study
- Comparative gut microbiome in diarrheal and non-diarrheal children: an individually matched case-control study
BibTeX
@article{li2026statematched,
title = {{State-matched redox nanomedicine for cell fate control and multicompartment therapeutic windows.}},
author = {Jiacheng Li and Jiazhen Liu and Jia Cai and Tu Xu and Kun Gao and Jinsong Zhang and Ning Luo and Yaguang Wang and Yuping Xie and Xingchen Peng},
journal = {Redox biology},
year = {2026},
month = oct,
doi = {10.1016/j.redox.2026.104426},
url = {https://europepmc.org/article/MED/42837695},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - State-matched redox nanomedicine for cell fate control and multicompartment therapeutic windows.
AU - Jiacheng Li
AU - Jiazhen Liu
AU - Jia Cai
AU - Tu Xu
AU - Kun Gao
AU - Jinsong Zhang
AU - Ning Luo
AU - Yaguang Wang
AU - Yuping Xie
AU - Xingchen Peng
PY - 2026
DA - 2026/10/05
JO - Redox biology
DO - 10.1016/j.redox.2026.104426
UR - https://europepmc.org/article/MED/42837695
AB - Tumors persist under sustained redox stress by coupling increased reactive-species production to antioxidant buffering, metabolic plasticity and multicellular support. This creates therapeutic vulnerabilities whose tractability depends on the biological state of the exposed compartment. Here, we frame redox nanomedicine as state-matched manipulation of oxidant flux, antioxidant buffering, oxygen and substrate availability, localization, duration and spatial coverage. We propose that therapeutic outcome emerges from chemistry, exposure and the presence of an executable redox dependency together with the machinery required for adaptation, apoptosis, ferroptosis, pyroptosis or cuproptosis. Redox perturbations also propagate through immune, vascular, stromal and metabolic compartments, generating both therapeutic benefits and liabilities. We therefore integrate redox-state dependence, cell-fate assignment, multicompartment effects and translational target engagement into a unified framework. A state-matched development strategy begins with a defined biological dependency, measures local exposure and target engagement, and uses pharmacokinetic, safety and biomarker data to refine product design and patient selection. This framework positions redox nanomedicine as mechanistically testable control of tumor redox states within a defined therapeutic window.
SN - 2213-2317
ER -